Sundic 2014.

Methods	Randomised clinical trial.
Participants	Country: Norway. Number randomised: 62. Post‐randomisation dropouts: 0 (0%). Revised sample size: 62. Mean age: 42 years. Number of women: 6 (9.7%). Symptomatic: not stated. Asymptomatic: not stated. Mean follow‐up period (for all groups): 3 months. Target used for iron reduction: serum ferritin ≤ 50 μg/L. Inclusion criteria: Aged ≥ 18 years. No previous treatment for haemochromatosis. Diagnosis of haemochromatosis, defined as: presence of a homozygous genotype for C282Y or H63D or compound heterozygous genotype for C282Y and H63D and serum ferritin > 300 ng/mL or a transferrin saturation > 50% OR heterozygous C282Y genotype and ferritin levels > 500 ng/mL or transferrin saturation > 50%. Exclusion criteria: Atypical haemochromatosis without any documented genetic aberration or exclusively due to mutations other than C282Y and H63D. Bodyweight < 65 kg. Initial haemoglobin level < 13.5 g/dL.
Interventions	Participants were randomly assigned to 2 groups. Group 1: therapeutic erythrocytapheresis (n = 30). Further details: 400 mL per single treatment bi‐weekly*. Group 2: phlebotomy (n = 32). Further details: 450 mL per single treatment weekly. Treatment duration: 12 weeks.
Outcomes	Adverse events.
Notes	We attempted to contact the corresponding author in June 2015 to obtain additional information on risk of bias and outcomes. We did not receive any reply. * It was unclear whether the authors meant 'bi‐weekly' to be once every two weeks or twice weekly.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "The randomisation procedure was centralised to one of the participating centres, using a randomly generated sequence".
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "different treatment".
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were 6 dropouts/withdrawal but data regarding tolerance reported.
Selective reporting (reporting bias)	High risk	Comment: no data about mortality but just tolerability.
For‐profit bias	Low risk	Quote: "Grants from Helse Vest RHF and Helse Fonna HF (public hospital trusts)".
Other bias	Low risk	Comment: no other risk of bias.